Insider-linked Regeneron (REGN) holder plans 2,036-share Rule 144 sale on NASDAQ

Rhea-AI Filing Summary

Regeneron Pharmaceuticals security holder plans to sell 2,036 common shares under Rule 144. The planned sale is through UBS Financial Services on NASDAQ, with an aggregate market value of 1,594,534.12 and 103,902,660 common shares stated as outstanding.

The shares to be sold were acquired from the issuer via two transactions: 1,000 shares through a cash exercise of stock options dated 02/09/2026, and 1,036 shares through a restricted stock award dated 12/08/2025.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	2036	1594534.12	103902660	02/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/09/2026	Exercise of Stock Options	Issuer			1000	02/09/2026	Cash
Common	12/08/2025	Restricted Stock Award	Issuer			1036	12/08/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for REGN disclose?

The Form 144 discloses that a Regeneron Pharmaceuticals security holder plans to sell 2,036 common shares. The transaction is to be executed through UBS Financial Services on NASDAQ, under Rule 144, with an aggregate market value of about 1,594,534.12.

How many Regeneron (REGN) shares are planned to be sold and at what value?

The filing shows a planned sale of 2,036 Regeneron common shares with an aggregate market value of 1,594,534.12. This implies a high per-share price and reflects the value of the securities at the time of the planned Rule 144 sale.

How were the REGN shares in this Form 144 acquired?

The 2,036 Regeneron shares were acquired directly from the issuer in two ways: 1,000 shares via a cash exercise of stock options on 02/09/2026, and 1,036 shares through a restricted stock award dated 12/08/2025.

When is the planned Rule 144 sale for Regeneron (REGN) shares?

The planned sale date listed is approximately 02/09/2026. This date reflects when the security holder expects to sell the 2,036 common shares on NASDAQ, subject to Rule 144 conditions and market execution through UBS Financial Services.

What is the total number of Regeneron (REGN) shares outstanding in this filing?

The Form 144 cites 103,902,660 Regeneron common shares as outstanding. This figure provides context for the planned 2,036-share sale, indicating the sale represents a very small portion of the company’s total outstanding common equity at that time.

Which broker and exchange are involved in the REGN Form 144 sale?

The filing states that UBS Financial Services, Inc., based at 11 Madison Avenue in New York, will handle the transaction. The 2,036 Regeneron common shares are planned to be sold on the NASDAQ exchange under Rule 144 resale provisions.